Answers are grounded in this paper and cite their sources.
Background/Objectives: The aim of this study is to obtain new inclusion complexes of fenbendazole (FEN) with hydroxypropyl-β-cyclodextrin (HP-β-CD) in order to optimize the in vitro release profile of fenbendazole from immediate-release tablets. Methods: Inclusion complexes and solid dispersions were prepared by coprecipitation, lyophilization, and kneading at 1:0.25 and 1:0.5 (FEN:HP-β-CD) sub-stoichiometric molar ratios. Physical mixtures were prepared for comparison. Both physical mixtures and inclusion complexes were subsequently evaluated using physicochemical and pharmacotehnical methods. Results: Physicochemical analysis (FTIR, XRD, and TG/DTA) showed that lyophilization successfully induced solid-state amorphization of the drug at both ratios. Directly compressed tablets exhibited excellent mechanical properties, with crushing strength ranging from 65.1 ± 2.4 N (F3) to 87.4 ± 2.9 N (F2) and 98.2 ± 3.5 N (F1), friability below 0.7%, and rapid disintegration (58 ± 3.2 s for F1, 69 ± 4.1 s for F2, and 77 ± 4.5 s for F3). In vitro dissolution was strongly medium-dependent: at pH 1.2, cyclodextrin-based tablets achieved near-complete dissolution within 60 min (Q60 = 96.8 ± 2.1, DE% = 81.8 ± 1.9% for F1; Q60 = 99.5 ± 1.8%, DE% = 71.4 ± 2.3% for F2), compared with the uncomplexed drug (Q60 = 63.3 ± 2.4%, DE% = 47.5 ± 1.7% for F3). At pH 4.5 and 6.8, drug release plateaued below 15% and 38%, respectively, due to non-sink saturation constraints. Conclusions: This study provides in vitro proof of concept that sub-stoichiometric amorphization with HP-β-CD, coupled with direct compression, overcomes the gastric dissolution barrier of fenbendazole, establishing a solid biopharmaceutical basis for future in vivo bioavailability and stability evaluations.
No takes yet. Share an insight, caveat, or question.
Pârvănescu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: